Phase 2 DIMENSION Study fails to meet primary endpoint Sage Therapeutics announced that its Phase 2 DIMENSION Study of dalzanemdor (SAGE-718) for cognitive impairment in Huntington’s disease failed to meet its primary and secondary endpoints. Dalzanemdor showed no statistically significant or clinically meaningful improvement versus placebo in the Symbol Digit Modalities Test at Day 84…
Unlocking the blood-brain barrier?
Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach—demonstrated in mouse models and isolated human brain tissue—to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases. 29 November 2024: Published in the November 25 online issue of Nature Biotechnology [https://doi.org/10.1038/s41587-024-02487-7],…
First UK Neuro Forum
UK Neuro Forum will focus on services and support for neuro conditions 28 November 2024: Andrew Gwynne MP, Parliamentary Under-Secretary of State at the Department of Health and Social Care, has announced today that a new UK Neuro Forum will be set up to find ways to improve care and support for people affected by…
Hearing loss associated with PD
A recent study using electronic health records from over 3 million U.S. veterans has identified hearing loss as an independent risk factor for developing Parkinson’s disease (PD). Published in JAMA Neurology, the research revealed that hearing loss increases PD risk even when adjusting for factors like age, head trauma, and prodromal disorders. Researchers suggested that…
Traumatic Brain Injury – more catastrophic in children?
Study reveals differences in brain pathology between paediatric and adult patients following traumatic brain injury 26 November 2024: A study led by Professor Willie Stewart from the University of Glasgow has revealed differences in the brains of paediatric and adult patients’ that might explain the sometimes catastrophic outcomes seen in children following a traumatic brain…
One-stop cardiology and neurology clinic
A unique one-stop clinic for people with Dravet syndrome has been launched at the Epilepsy Society’s Chalfont Centre 26 November 2024: The service, thought to be the only one of its kind in the UK, is designed to reduce the number of clinical appointments a person has to attend, reducing stress and accelerating any treatment…
AI detects voice changes in PD
26 November 2024: Algorithms that can detect subtle voice changes in PD are emerging as a potential new diagnostic tool for Parkinson’s disease, according to researchers from Iraq and Australia. Speech impairments are often the first indicators of Parkinson’s disease, but traditional diagnostic methods are often complex and slow, delaying early detection. Researchers from Middle Technical…
Reducing dysbiosis and gastrointestinal issues in PD
Parkinson’s drug changes the gut microbiome for the worse due to iron deficiency 21 November 2024: In a new study, conducted within the framework of the FWF-funded Cluster of Excellence “Microbiomes drive Planetary Health”, scientists from the University of Vienna, in collaboration with the University of Southampton, Aalborg University and Boston University, have revealed that…
What patients think of pharma
Issues influencing neurology patient groups in 2023 PatientView’s 2024 report, Patients in Action, examines how patient groups, including those specialising in neurological conditions, view their roles in national healthcare systems. Findings from this survey, which included responses from neurology-focused groups, were compared with 19 other therapeutic areas, revealing key insights into neurology patient groups’ perspectives…
